NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$31.29
-0.55 (-1.73%)
Close of Nov 06, 2026 · end-of-day data
MD 8-K filings in 2026
Every material Form 8-K Pediatrix Medical filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% from $492.9 million a year earlier, and adjusted EPS of $0.72 versus $0.67. GAAP net income fell to $47.0 million, or $0.59 per diluted share, from $71.7 million, or $0.84, and adjusted EBITDA declined to $85.5 million from $87.3 million. The company also projects full-year 2026 adjusted EBITDA of $290 million to $300 million.
Q3 net revenue $501.4 million vs. $492.9 million in Q3 2025, up 1.7%
Q3 net income $47.0 million ($0.59 diluted EPS) vs. $71.7 million ($0.84), including a $20.9 million investment gain in the prior-year quarter
Q3 adjusted EPS $0.72 vs. $0.67; adjusted EBITDA $85.5 million vs. $87.3 million
Full-year 2026 adjusted EBITDA outlook of $290 million to $300 million
Pediatrix Medical Group reported second-quarter 2026 revenue of $487.8 million, up 4.0% from a year earlier, and net income of $39.8 million, or $0.49 per diluted share, compared with $0.46 in the prior-year quarter. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, though same-unit patient volume fell 2.1%.
Q2 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier
Net income of $39.8 million, or $0.49 per diluted share, vs. $0.46 in Q2 2025
Adjusted EPS of $0.63 vs. $0.53; Adjusted EBITDA of $76.4 million vs. $73.2 million
Full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million reaffirmed; same-unit volume down 2.1%
Pediatrix Medical Group said its General Counsel, Chief Administrative Officer and Secretary, Mary Ann E. Moore, will serve in an advisory role until October 31, 2026, when she leaves the company. The company also named David Haddock as Executive Vice President, General Counsel and Secretary, a senior legal role that shareholders may watch as the transition takes effect.
Mary Ann E. Moore's transition is a termination without cause under her employment agreement, with benefits specified in that agreement.
Moore will serve in an advisory role until October 31, 2026, under a Separation Agreement signed July 21, 2026.
David Haddock was appointed Executive Vice President, General Counsel and Secretary.
The company first reported the planned transition on May 1, 2026.
Pediatrix Medical Group said in a July 15, 2026 update on its second quarter that its payor mix stayed stable and in line with recent trends and internal expectations, and it has not seen material changes in other net revenue trends. The company reaffirmed its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million, and it did not report second quarter financial results in this filing. Full results are due in a release on August 4, 2026.
Full year 2026 Adjusted EBITDA outlook reaffirmed at $280 million to $300 million
Second quarter payor mix stable and unchanged relative to recent historical trends and internal expectations
Company says it has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector
Investor conference call and detailed results release scheduled for August 4, 2026, at 9:00 a.m. ET
At its May 7, 2026 annual meeting, Pediatrix Medical Group's shareholders approved the Second Amended and Restated 2008 Incentive Compensation Plan, which adds 8,000,000 shares for issuance under the plan. All nine director nominees were elected, and shareholders ratified PricewaterhouseCoopers LLP as auditor and approved executive pay on an advisory basis. John M. Starcher, Jr. received notably more votes against than for, which shareholders may wish to note.
Plan approved with 65,912,243 votes for and 6,303,675 against; the plan adds 8,000,000 shares
John M. Starcher, Jr. received 46,296,745 votes for and 25,909,618 against in his director election
PricewaterhouseCoopers LLP ratified as 2026 independent auditor with 75,519,473 votes for
Pediatrix Medical Group reported first-quarter 2026 results, with net revenue of $476.2 million, up from $458.4 million a year earlier, and net income of $29.6 million, or $0.36 per diluted share, compared with $0.24 in the prior-year quarter. The company reaffirmed its full-year 2026 Adjusted EBITDA range of $280 million to $300 million, which gives shareholders a continued outlook for the year.
Q1 2026 Adjusted EBITDA was $58.2 million, compared with $49.2 million in Q1 2025.
Adjusted EPS was $0.44, compared with $0.33 in the prior-year quarter.
Same-unit volume-driven revenue decreased 1.6 percent, while reimbursement-related factors increased same-unit revenue by 4.4 percent.
Full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million was reaffirmed; cash and equivalents were $205.8 million at March 31, 2026.
Pediatrix Medical Group reported fourth-quarter 2025 net income of $33.7 million, or $0.40 per diluted share, up from $0.36 a year earlier, while net revenue fell to $493.8 million from $502.4 million and Adjusted EBITDA fell to $65.8 million from $68.7 million. For full-year 2025, net income was $165.4 million, or $1.94 per share, compared with a net loss in 2024, and the company preliminarily expects 2026 Adjusted EBITDA of $280 million to $300 million.
Q4 2025 net revenue of $493.8 million vs $502.4 million in Q4 2024; same-unit revenue grew 4.0 percent, offset by practice dispositions
Q4 2025 net income of $33.7 million, or $0.40 per diluted share, vs $30.5 million, or $0.36, in Q4 2024; Adjusted EPS was $0.50 vs $0.51
Full-year 2025 net income of $165.4 million ($1.94 per share) vs a net loss of $99.1 million ($1.19 per share) in 2024
Preliminary 2026 Adjusted EBITDA outlook of $280 million to $300 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pediatrix Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →